Study summary

Erenumab did not help chronic cluster headache

Erenumab trial · Randomized, placebo-controlled · Published June 2025, JAMA Network Open

What was tested

Erenumab, a monthly CGRP-receptor antibody approved for migraine, against placebo for chronic cluster headache.

What they found

The share of people whose attacks halved was not better than placebo (31.7% vs about 45%).

What it means

CGRP blockers are not a reliable option for chronic cluster headache.

JAMA Netw Open, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.